retatrutide eli lilly press release 2024 2025 Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial Lilly's New Obesity Drug Names
Description
Heres the core of the issue
And some that look promising today will fail for reasons that have nothing to do with efficacy
If those first two sound familiar, it's because the current generation of weight loss medications already targets them
GH secretagogues are compounds that signal the pituitary gland to release more of the growth hormone your body already produces, rather than replacing the hormone itself
This evolving competition is expected to drive innovation in areas such as delivery devices, patient adherence tools, and real-world clinical data generation
